Literature DB >> 15468162

Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.

Shu-Chin Yip1, Mirvat El-Sibai, Karen M Hill, Haiyan Wu, Zheng Fu, John S Condeelis, Jonathan M Backer.   

Abstract

Phosphoinositide 3-kinase (PI 3-kinase) activity is required for growth factor-induced cytoskeletal regulation and cell migration. We previously found that in MTLn3 rat adenocarcinoma cells, EGF-stimulated induction of actin barbed ends and lamellipod extension specifically requires the p85/p110alpha isoform of PI 3-kinase. To further characterize signaling by distinct PI 3-kinase isoforms, we have developed MTLn3 cells that transiently or stably overexpress either p110alpha or p110beta. Transient overexpression of p110beta inhibited EGF-stimulated lamellipod extension, whereas p110alpha-transfected cells showed normal EGF-stimulated lamellipod extension. Similar results were obtained by overexpression of kinase-dead p110beta, suggesting that effects on cytoskeletal signaling were due to competition with p85/p110alpha complexes. Stable overexpression of p110alpha appeared to be toxic, based on the difficulty in obtaining stable overexpressing clones. In contrast, cells expressing a 2-fold increase in p110beta were readily obtainable. Interestingly, cells stably expressing p110beta showed a marked inhibition of EGF-stimulated lamellipod extension. Using computer-assisted analysis of time-lapse images, we found that overexpression of p110beta caused a nearly complete inhibition of motility. Cells overexpressing p110beta showed normal activation of Akt and Erk, suggesting that overall PI 3-kinase signaling was intact. A chimeric p110 molecule containing the p85-binding and Ras-binding domains of p110alpha and the C2, helical, and kinase domains of p110beta, was catalytically active yet also inhibited EGF-stimulated lamellipod extension. These data highlight the differential signaling by distinct p110 isoforms. Identification of effectors that are differently regulated by p110alpha versus p110beta will be important for understanding cell migration and its role in metastasis. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15468162     DOI: 10.1002/cm.20032

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  10 in total

1.  A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.

Authors:  Hashem A Dbouk; Huan Pang; Andras Fiser; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

2.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.

Authors:  Sohye Kang; Adam Denley; Bart Vanhaesebroeck; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 3.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

Review 4.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

5.  Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.

Authors:  Amit Kumar; Javier Redondo-Muñoz; Vicente Perez-García; Isabel Cortes; Monica Chagoyen; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2011-03-07       Impact factor: 4.272

Review 6.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07

Review 7.  Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases.

Authors:  Rachel Schnur Salamon; Jonathan M Backer
Journal:  Bioessays       Date:  2013-07       Impact factor: 4.345

8.  Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins.

Authors:  Ping Wang; Puneet Kumar; Chang Wang; Kathryn A Defea
Journal:  Biochem J       Date:  2007-12-01       Impact factor: 3.857

Review 9.  Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Authors:  Yoshihiro Ito; Jonathan R Hart; Peter K Vogt
Journal:  Expert Opin Ther Targets       Date:  2018-09-24       Impact factor: 6.902

10.  PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.

Authors:  Hua-Fu Zhao; Jing Wang; Hao-Ran Jiang; Zhong-Ping Chen; Shing-Shun Tony To
Journal:  J Exp Clin Cancer Res       Date:  2016-05-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.